157 related articles for article (PubMed ID: 7200956)
21. In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions.
Wu ZQ; Vos Q; Shen Y; Lees A; Wilson SR; Briles DE; Gause WC; Mond JJ; Snapper CM
J Immunol; 1999 Jul; 163(2):659-67. PubMed ID: 10395655
[TBL] [Abstract][Full Text] [Related]
22. The antibody response to secondary immunization with pneumococcal polysaccharides in mice.
Aaberge IS; Løvik M
Scand J Immunol; 1995 Dec; 42(6):617-25. PubMed ID: 8552985
[TBL] [Abstract][Full Text] [Related]
23. The effect of T cell independent and cross-reactive antigen on the immune response to pneumococcal conjugate vaccination.
Rabquer B; Smithson SL; Shriner A; Julie Westerink MA
Immunol Lett; 2006 Aug; 106(2):187-90. PubMed ID: 16781780
[TBL] [Abstract][Full Text] [Related]
24. Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates.
Safari D; Dekker HA; Rijkers G; Snippe H
Vaccine; 2011 Jan; 29(4):849-54. PubMed ID: 21111776
[TBL] [Abstract][Full Text] [Related]
25. Antibody response to pneumococcal polysaccharide vaccine in young, adult and old mice.
Aaberge IS; North RJ; Groeng EC; Løvik M
Scand J Immunol; 1993 Jul; 38(1):17-30. PubMed ID: 8327857
[TBL] [Abstract][Full Text] [Related]
26. A murine model for the study of immune memory in response to pneumococcal conjugate vaccination.
Moreno RL; Sampson JS; Romero-Steiner S; Wong B; Johnson SE; Ades E; Carlone GM
Vaccine; 2004 Aug; 22(23-24):3069-79. PubMed ID: 15297057
[TBL] [Abstract][Full Text] [Related]
27. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
Madoff LC; Paoletti LC; Tai JY; Kasper DL
J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
[TBL] [Abstract][Full Text] [Related]
28. IgG2 subclass restriction of antibody to pneumococcal polysaccharides.
Barrett DJ; Ayoub EM
Clin Exp Immunol; 1986 Jan; 63(1):127-34. PubMed ID: 3955880
[TBL] [Abstract][Full Text] [Related]
29. Kinetics of the antibody response to type III pneumococcal polysaccharide. II. Factors influencing the serum antibody levels after immunization with an optimally immunogenic dose of antigen.
Jones JM; Amsbaugh DF; Prescott B
J Immunol; 1976 Jan; 116(1):52-64. PubMed ID: 1446
[TBL] [Abstract][Full Text] [Related]
30. Altered response to pneumococcal polysaccharide in offspring of immunologically paralyzed mice.
Kerman R; Segre D; Myers WL
Science; 1967 Jun; 156(3781):1514-6. PubMed ID: 4388423
[TBL] [Abstract][Full Text] [Related]
31. Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.
Richter MY; Jakobsen H; Haeuw JF; Power UF; Jonsdottir I
Infect Immun; 2005 Feb; 73(2):956-64. PubMed ID: 15664938
[TBL] [Abstract][Full Text] [Related]
32. Production and characterization of monoclonal antibodies specific for types 6 and 19 pneumococcal capsular polysaccharides.
Milligan GN; Braley-Mullen H
Mol Immunol; 1989 Sep; 26(9):799-807. PubMed ID: 2601723
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates.
Beuvery EC; van Rossum F; Nagel J
Infect Immun; 1982 Jul; 37(1):15-22. PubMed ID: 6809623
[TBL] [Abstract][Full Text] [Related]
34. Pneumococcal polysaccharide immunization of children with sickle cell disease. II. Serologic response and pneumococcal disease following immunization.
Overturf GD; Selzer JW; Chan L; Weiss J; Field R; Rigau-Perez JG; Powars D; Uy C; Pang EJ; Honig G; Steele R; Edmonds R; Portnoy B
Am J Pediatr Hematol Oncol; 1982; 4(1):25-35. PubMed ID: 7091574
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
36. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
Lin H; Peng Y; Lin Z; Zhang S; Guo Y
Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of antibody responses to pneumococcal vaccines with ELISA and opsonophagocytic assay.
Kim KH; Seoh JY
J Korean Med Sci; 1999 Oct; 14(5):475-9. PubMed ID: 10576141
[TBL] [Abstract][Full Text] [Related]
38. Antibody- and cell-mediated immune responses to a synthetic oligosaccharide conjugate vaccine after booster immunization.
Safari D; Dekker HA; de Jong B; Rijkers GT; Kamerling JP; Snippe H
Vaccine; 2011 Sep; 29(38):6498-504. PubMed ID: 21767596
[TBL] [Abstract][Full Text] [Related]
39. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.
Buchwald UK; Lees A; Steinitz M; Pirofski LA
Infect Immun; 2005 Jan; 73(1):325-33. PubMed ID: 15618169
[TBL] [Abstract][Full Text] [Related]
40. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.
Paton JC; Lock RA; Lee CJ; Li JP; Berry AM; Mitchell TJ; Andrew PW; Hansman D; Boulnois GJ
Infect Immun; 1991 Jul; 59(7):2297-304. PubMed ID: 2050399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
